| Code | CSB-RA004929MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Mezagitamab, targeting CD38 (cluster of differentiation 38), a type II transmembrane glycoprotein with both enzymatic and receptor functions. CD38 catalyzes the synthesis and hydrolysis of cyclic ADP-ribose and ADP-ribose from NAD+, playing crucial roles in calcium signaling, cell adhesion, and signal transduction. This protein is highly expressed on various immune cells and is significantly upregulated in hematological malignancies, particularly multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, making it an important therapeutic target in oncology.
Mezagitamab is a humanized IgG1 monoclonal antibody designed to bind CD38 with high affinity, mediating tumor cell death through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction. This biosimilar antibody serves as a valuable research tool for investigating CD38 biology, exploring immune cell function, studying hematological cancer pathogenesis, and evaluating potential therapeutic mechanisms in preclinical models of B-cell and plasma cell disorders.
There are currently no reviews for this product.